Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.


Related Content

FDA Status Updates On Citizen Petitions Would Not Signal Decision Pending
FDA To Implement Live Citizen Petition Status Updates
Biosimilar Labeling: FDA Says Leave Comparability Data Out
Biosimilar Substitution: 'Devil' Is In Barriers To Switch In State Laws
FDA Sets New Goal For Biosimilar, Drug Promotion Guidances
Can FDA Do The "Right Thing" On Transparency? Ask A Lawyer
Sharfstein Heads FDA Transparency Task Force


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts